Skip to main content

Antidepressant Use May Speed Up Cognitive Decline in Patients With Dementia

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 5, 2025.

via HealthDay

WEDNESDAY, March 5, 2025 -- Current antidepressant use is associated with faster cognitive decline in patients with dementia, according to a study published online Feb. 25 in BMC Medicine.

Minjia Mo, Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the association between antidepressants and cognitive decline in patients with dementia in a national cohort study. Data were included for 18,740 patients, of whom 22.8 percent received at least one prescription for an antidepressant.

The researchers found that 11,912 prescriptions for antidepressants were issued during follow-up, with selective serotonin reuptake inhibitors (SSRI) being the most common (64.8 percent). Compared with nonuse, there was an association for antidepressant use with faster cognitive decline (β = −0.30 points/year), especially for sertraline, citalopram, escitalopram, and mirtazapine (β = −0.25, −0.41, −0.76, and −0.19 points/year, respectively). Patients with severe dementia (initial Mini-Mental State Examination scores 0 to 9) had a stronger association. A greater rate of decline was seen for escitalopram than sertraline. Dose response of SSRIs on greater cognitive decline and higher risks for severe dementia, all-cause mortality, and fracture were seen compared with nonuse.

"Our study cannot distinguish whether these findings are due to the antidepressants or the underlying psychiatric indication," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes

THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...

ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes

THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...

2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes

THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.